Breaking News Instant updates and real-time market news.

REGN

Regeneron

$355.53

0.09 (0.03%)

14:33
11/06/18
11/06
14:33
11/06/18
14:33

Regeneron operational performance, diversifying pipeline on display in Q3, says Piper Jaffray

Piper Jaffray analyst Christopher Raymond reiterates an Overweight rating and $450 price target on Regeneron's shares following Q3 top- and bottom-line beats. The analyst notes that over the last five quarters including Q3, EPS has beaten consensus on average by 55c, consistently driven by top-line beats. Combining strong operational performance with continued pipeline maturation and commercial momentum, the analyst continues to like the setup and remains a buyer.

  • 06

    Nov

  • 27

    Nov

  • 11

    Mar

  • 28

    Apr

  • 13

    May

REGN Regeneron
$355.53

0.09 (0.03%)

10/17/18
JEFF
10/17/18
NO CHANGE
Target $31
JEFF
Buy
Jefferies still sees 'major' opportunity for Optinose after Dupixent data
Optinose (OPTN) shares underperformed yesterday following the positive Phase 3 results for Sanofi (SNY) and Regeneron's (REGN) Dupixent in treating patients with chronic rhinosinusitis with nasal polyps, Jefferies analyst David Steinberg tells investors in a research note titled "Biologics Competitor as Expected; Real World Pricing Issues Likely to Limit Us." The analyst says that while Dupixent demonstrated strong efficacy, clinicians he's spoken with believe that the "massive" pricing disparity versus nasal steroids will likely result in payer "step edits" that could limit widespread adoption of the "expensive" biologics currently under development. Further, Dupixent's head-to-head comparison with Optinose's Xhance's "strong" efficacy profile is difficult, the analyst adds. Steinberg still sees a "major" long-term opportunity for Xhance and keeps a Buy rating on Optinose with a $31 price target.
10/22/18
PIPR
10/22/18
NO CHANGE
Target $450
PIPR
Overweight
Regeneron asthma label for Dupixent broad as hoped, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says that while Regeneron Pharmaceuticals' asthma label for Dupixent does not broadly cover patients regardless of eosinophilic phenotype as he had anticipated, it does cover oral corticosteroid dependent patients regardless of eosinophilic phenotype, which essentially matches his modeling. Moreover, the analyst notes that the label covers all patients 12 and older, and both moderate and severe disease. As such, he sees the label as broad, "but not necessarily as anticipated." The analyst is making no change to his numbers based on the label and keeps an Overweight rating on Regeneron with a $450 price target.
10/22/18
CANT
10/22/18
NO CHANGE
Target $441
CANT
Neutral
Regeneron price target raised to $441 from $419 at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young raised her price target for Regeneron Pharmaceuticals to $441 citing Dupixent's label in asthma, which she thinks is broad. The analyst believes the shares could trade up 5% on the label but she keeps a Neutral rating on the name. Dupixent expectations are high already, Young tells investors in a research note.
10/29/18
MSCO
10/29/18
NO CHANGE
MSCO
Equal Weight
Morgan Stanley sees little impact to Regeneron from competitor data at AAO
Morgan Stanley analyst Matthew Harrison noted that data was presented at the American Academy of Ophthalmology's annual meeting for three potential competitors to Regeneron's (REGN) Eylea - Allergan's (AGN) abicipar pegol, Novartis' (NVS) brolucizumab and Roche's (RHHBY) faricimab. Following the presentations, his view on abicipar and brolucizumab is unchanged and he awaits further late-stage data from faricimab, said Harrison, who sees little impact to Regeneron based on the new data. He maintains an Equal Weight rating on Regeneron shares.

TODAY'S FREE FLY STORIES

ADS

Alliance Data

$198.00

0.38 (0.19%)

09:18
11/19/18
11/19
09:18
11/19/18
09:18
Recommendations
Alliance Data analyst commentary  »

Alliance Data price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CORT

Corcept Therapeutics

$13.02

0.005 (0.04%)

09:18
11/19/18
11/19
09:18
11/19/18
09:18
Hot Stocks
Corcept Therapeutics doses first patient in Phase 3 trial of relacorilant »

Corcept Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

09:18
11/19/18
11/19
09:18
11/19/18
09:18
Options
Overnight activity included 313 trades in SPX and 10 trades in VIX »

313 trades were executed…

SPX

S&P 500

$0.00

(0.00%)

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLTZY

Tele2

$0.00

(0.00%)

09:17
11/19/18
11/19
09:17
11/19/18
09:17
Upgrade
Tele2 rating change  »

Tele2 upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKER

Akers Biosciences

$1.23

-0.365 (-22.88%)

09:16
11/19/18
11/19
09:16
11/19/18
09:16
Hot Stocks
Akers Biosciences considering business combinations in cannabis related industry »

Akers Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APDN

Applied DNA Sciences

$1.08

-0.015 (-1.37%)

09:15
11/19/18
11/19
09:15
11/19/18
09:15
Hot Stocks
Applied DNA Sciences, Eurofins sign collaboration agreement »

Applied DNA Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REN

Resolute Energy

$30.51

0.67 (2.25%)

, VKTX

Viking Therapeutics

$11.65

0.27 (2.37%)

09:14
11/19/18
11/19
09:14
11/19/18
09:14
Hot Stocks
Fly Intel: Pre-market Movers »

HIGHER: Resolute Energy…

REN

Resolute Energy

$30.51

0.67 (2.25%)

VKTX

Viking Therapeutics

$11.65

0.27 (2.37%)

ZAYO

Zayo Group

$23.70

1.495 (6.73%)

LEJU

Leju

$1.71

0.05 (3.01%)

JD

JD.com

$23.04

-1.18 (-4.87%)

XEC

Cimarex Energy

$88.63

-0.27 (-0.30%)

PCG

PG&E

$24.39

6.62 (37.25%)

MDGL

Madrigal Pharmaceuticals

$129.47

-3.36 (-2.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 03

    Dec

IRT

Independence Realty Trust

$9.99

0.21 (2.15%)

09:14
11/19/18
11/19
09:14
11/19/18
09:14
Initiation
Independence Realty Trust initiated  »

Independence Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACC

American Campus

09:14
11/19/18
11/19
09:14
11/19/18
09:14
Initiation
American Campus initiated  »

American Campus initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UDR

UDR, Inc.

$41.06

0.6 (1.48%)

09:14
11/19/18
11/19
09:14
11/19/18
09:14
Initiation
UDR, Inc. initiated  »

UDR, Inc. initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMRN

Immuron

$8.50

(0.00%)

, SGYP

Synergy Pharmaceuticals

$0.39

0.0211 (5.73%)

09:13
11/19/18
11/19
09:13
11/19/18
09:13
Hot Stocks
Immuron appoints Gary Jacob CEO »

Immuron (IMRN) announced…

IMRN

Immuron

$8.50

(0.00%)

SGYP

Synergy Pharmaceuticals

$0.39

0.0211 (5.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

INTC

Intel

$48.85

0.73 (1.52%)

09:12
11/19/18
11/19
09:12
11/19/18
09:12
Recommendations
Intel analyst commentary  »

Intel to benefit from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 04

    Dec

OTEX

OpenText

$33.20

0.32 (0.97%)

09:10
11/19/18
11/19
09:10
11/19/18
09:10
Hot Stocks
Sun Chemical selects OpenText to improve customer service »

OpenText announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BFIN

BankFinancial

$14.55

0.17 (1.18%)

09:09
11/19/18
11/19
09:09
11/19/18
09:09
Hot Stocks
BankFinancial extends, expands share repurchase program »

BankFinancial announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMHC

Houghton Mifflin

$8.84

-0.12 (-1.34%)

09:09
11/19/18
11/19
09:09
11/19/18
09:09
Hot Stocks
Houghton Mifflin: Texas SBE approves new K-8 reading programs »

Houghton Mifflin Harcourt…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEJU

Leju

$1.71

0.05 (3.01%)

09:06
11/19/18
11/19
09:06
11/19/18
09:06
Earnings
Breaking Earnings news story on Leju »

Leju sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

LEJU

Leju

$1.71

0.05 (3.01%)

09:06
11/19/18
11/19
09:06
11/19/18
09:06
Earnings
Leju reports Q3 adj. EPS 8c, one estimate (2c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

GLYC

GlycoMimetics

$11.94

0.34 (2.93%)

09:05
11/19/18
11/19
09:05
11/19/18
09:05
Hot Stocks
GlycoMimetics enrolls first patient in Phase 3 clinical trial of uproleselan »

GlycoMimetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WBA

Walgreens Boots Alliance

$82.54

0.25 (0.30%)

, CVS

CVS Health

$79.33

-0.48 (-0.60%)

09:05
11/19/18
11/19
09:05
11/19/18
09:05
Hot Stocks
Florida AG amends opioid lawsuit complaint to include Walgreens, CVS »

Attorney General Pam…

WBA

Walgreens Boots Alliance

$82.54

0.25 (0.30%)

CVS

CVS Health

$79.33

-0.48 (-0.60%)

INSY

Insys Therapeutics

$7.08

-0.13 (-1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

DISH

Dish

$32.85

-0.25 (-0.76%)

, CTL

CenturyLink

$19.16

0.19 (1.00%)

09:02
11/19/18
11/19
09:02
11/19/18
09:02
Hot Stocks
Dish names Atilla Tinic as Chief Information Officer »

DISH (DISH) announced…

DISH

Dish

$32.85

-0.25 (-0.76%)

CTL

CenturyLink

$19.16

0.19 (1.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

AVNW

Aviat Networks

$14.92

-0.43 (-2.80%)

, MSI

Motorola Solutions

$129.97

0.72 (0.56%)

09:01
11/19/18
11/19
09:01
11/19/18
09:01
Hot Stocks
Aviat Networks selected by Motorola Solutions for Florida's P25 network »

Aviat Networks (AVNW)…

AVNW

Aviat Networks

$14.92

-0.43 (-2.80%)

MSI

Motorola Solutions

$129.97

0.72 (0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 04

    Dec

  • 18

    Dec

  • 19

    Dec

YETI

Yeti

$16.99

0.1 (0.59%)

09:00
11/19/18
11/19
09:00
11/19/18
09:00
Initiation
Yeti initiated  »

Yeti initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

GE

General Electric

$8.04

-0.135 (-1.65%)

08:57
11/19/18
11/19
08:57
11/19/18
08:57
Hot Stocks
GE announces new leadership in Power reorganization »

GE recently announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$8.04

-0.135 (-1.65%)

, FB

Facebook

$139.55

-4.31 (-3.00%)

08:55
11/19/18
11/19
08:55
11/19/18
08:55
Options
Notable open interest changes for November 19th »

Friday's total…

GE

General Electric

$8.04

-0.135 (-1.65%)

FB

Facebook

$139.55

-4.31 (-3.00%)

NVDA

Nvidia

$164.38

-38.27 (-18.88%)

JD

JD.com

$23.04

-1.18 (-4.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 26

    Nov

  • 28

    Nov

  • 10

    Dec

BKI

Black Knight

$49.77

0.87 (1.78%)

08:55
11/19/18
11/19
08:55
11/19/18
08:55
Conference/Events
Black Knight to host Investor Day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 03

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.